FDA approves GSK's long-acting HIV drug Cabenuva for teens

Compilenewborn

Recently, ViiV Healthcare, an HIV pharmaceutical company controlled by GlaxoSmithKline, announced that the U.

The approval of Cabenuva is the first long-acting HIV therapy for adolescents

Currently, Cabenuva offers co-packages of two injectable drugs: ViiV's cabotevir extended-release injection suspension single-dose vial, and Janssen's rilpivirine extended-release injection suspension single-dose vial

It is reported that HIV-infected adolescents face greater challenges in daily oral HIV treatment, and face the pressure and difficulty of daily medication

The FDA approval to expand the treatment population of Cabenuva is based on data from the adult study and the interim analysis at Week 16 of the MOCHA study

Reference source: ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg